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Introduction
 Hereditary Hemochromatosis (HH) is a genetic disorder resulting 
in iron overload. The HFE-gene related subtype 1 is the most common 
cause of HH in Northern Europe. The inheritance is autosomal reces-
sive and penetrance is between 13.5 and 50%. About 80-90% of pa-
tients with HH have a mutation in C282Y on the HFE-gene resulting 
in hepcidin dysfunction [1-3]. In HH, dysfunctional hepcidin leads to 
increased iron uptake in the duodenum via ferroportin and increased 
release of iron from deposits in macrophages [4]. The iron accumu-
lates in several organs including the liver, pancreas, pituitary glands, 
heart and skin. In hereditary hemochromatosis phlebotomy is recom-
mended to remove the excess iron that is toxic to cells. Increased iron 
deposits in the liver and pancreas may lead to cirrhosis, hypogonado-
tropic hypogonadism and diabetes. The frequency of endocrine insuf-
ficiencies in HH is debated [5-9]. A study including patients with HH 
related cirrhosis found endocrine dysfunction in nine of nine patients. 
However, a more recent study found that 5% of women and 6% of men 
with HH had Hypogonadotropic hypogonadism and a similar study 
found that only one patient out of 22 (5%) had a borderline gonado-
tropic deficient [9,10]. However, there are no studies evaluating the in-
fluence of pituitary dysfunction and the quality of life in patients with 
HH [11]. A cross sectional study found that pituitary dysfunction due 
to surgery or chemotherapy lead to reduced quality of life. Pituitary 
dysfunction may have a similar impact on the quality of life in patients 
with HH [12]. Therefore, we evaluated the association between the 
quality of life, ferritin and pituitary hormones in patients with HH. 
Ferritin levels are used to evaluate the treatment with a target level of 
50 to 100 µg/L. Alleviating the iron overload is believed to decrease 
the risk of complications including diabetes, osteoporosis and cirrho-
sis. It may also reduce the risk of pituitary dysfunction. Whether phle-
botomy improves health related quality of life is debated [13,14-16].
Materials and Methods
Patients
 We recruited all consecutive adult patients with genetically verified 
HH undergoing phlebotomy from the outpatient clinics at four Dan-
ish University Hospitals (Aalborg University Hospital and Copenha-
gen University Hospitals Hvidovre, Gentofte and Koege) from 2010 
to 2011. Our inclusion criteria were age > 18 years, a verified muta-
tion on the HFE gene (C282Y and H63D homozygote’s). Patients with 
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Abstract
Background: Hereditary Hemochromatosis (HH) can lead to com-
plications including cirrhosis, diabetes and osteoporosis and pitu-
itary dysfunction. The recommended initial treatment is phlebotomy 
adjusted based on ferritin levels. The extent to which HH affects the 
quality of life is not known.
Aim: To evaluate the quality of life patients with HH.
Methods: We included all patients with genetically verified HH un-
dergoing phlebotomy at four clinical sites in Denmark. Evidence of 
complications was systematically assessed. Quality of life was as-
sessed using the Short Form 36 (SF-36) questionnaire. Predictors 
of the quality of life (SF-36 total score) were evaluated in univariable 
and multivariable regression analysis.
Results: Twenty five patients (median age 60 years; 13 men) were 
included. The median number of times patients underwent phleboto-
my in the year before inclusion was 6 (range 4-8). Four patients had 
impaired glucose tolerance, two had diabetes, nine had a borderline 
response to the Synacthen test and two had evidence of hypogo-
nadotropic hypogonadism. In multivariable regression analyses, 
only ferritin was a significant predictor of the quality of life (P=0.031).
Conclusion: This study found that a low ferritin may be having a 
detrimental effect on the quality of life in patients with HH. Based 
on the small sample size, we cannot make any definite conclusions. 
The results suggest that the quality of life may be considered when 
evaluating treatment goals, e.g., in the elderly with a low risk of com-
plications, but additional research is needed to evaluate our findings.
Keywords: Hereditary disease; Iron overload related disease; Liver 
disease; Serum ferritin; Transferrin saturation
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other possible causes of iron overload e.g., secondary iron overload 
due to transfusion or erythropoiesis disorders, excessive alcohol in-
take (>24 g alcohol/day for women and >36g alcohol/day for men) or 
ongoing infections were excluded.
Ethics
 All patients gave their written informed consent according to the 
declaration of Helsinki. Scientific Ethics Committee Capital Region of 
Denmark and the Danish data protection agency approved the study.
Outcomes
 The primary outcome was quality of life assessed by the Short Form 
36 questionnaire (SF-36). SF-36 is an international validated question-
naire used to evaluate the general state of health. The questionnaire 
uncovers emotional wellbeing, role limitations due to emotional and 
physical health problems, physical functioning, bodily pain, social 
functioning, energy or fatigue and general health perceptions. Each 
parameter is scored from 0 (worst well-being) to 100 (best well-being) 
[17].
Participant characteristics and laboratory assessments
 We registered the baseline characteristics of included participants 
based on patient history and conducted a clinical and biochemical 
evaluation. Baseline data included age, gender, year of diagnosis, age 
at diagnosis, number of phlebotomy, known HH-related complica-
tions, comorbidities and the Charlson Comorbidity Index. Labora-
tory assessments included serum ferritin, hemoglobin, serum iron, 
transferrin saturation and liver blood tests [18]. Pituitary function was 
evaluated by Insulin-like Growth Factor-1 (IGF-1), Thyroid Stimulat-
ing Hormone (TSH), Thyroxine (T4), Triiodothyronine (T3), prolac-
tin, Luteinizing Hormone (LH) and Sex Hormone Binding Globulin 
(SHBG). We measured Follicle-Stimulating Hormone (FSH) and es-
trogen in female patients and testosterone in male patients. All tests 
were performed using hospital standard analysis and the results of pa-
tients were evaluated individually.
 Patients underwent an Adrenocorticotropic Hormone (ACTH) 
test with Synacthen (250 mg tetracosactide, synthetic corticotropin). 
We defined a normal response as plasma cortisol levels >550 nmol/L 
and an increase of >250 nmol/L, 30 minutes after Synacthen injection 
and a borderline response as values between 400 -549 nmol/L. Glucose 
tolerance was tested by an Oral Glucose Tolerance Test (OGTT). We 
defined diabetes as an OGTT with blood glucose levels >11 mmol/L 
after two hours, while patients with glucose values between 7.9 and 
11.0 mmol/L were classed as having impaired glucose tolerance. As-
sessment of the bone mineral density was performed by Dual-energy 
X-ray Absorptiometry (DXA) scan [19].
 We evaluated the health-related quality of life using the Short 
Form 36 (SF-36) questionnaire. The SF-36 is an internationally vali-
dated questionnaire used to evaluate the general state of health. The 
questionnaire uncovers emotional well-being, role limitations due to 
emotional problems, role limitation due to physical health problems, 
physical functioning, bodily pain, social functioning, energy/fatigue 
and general health perceptions [20].
Statistics
 The statistical analyses were performed in STATA version 14 (STA-
TA Corp, Texas, USA). Patient characteristics were summarized us-
ing medians with range for continuous variables or proportions for 
binary variables. Our analyses evaluated the potential predictors in 
univariable and multivariable linear regression analyses with back-
ward elimination. To evaluate the influence of having a low ferritin 
level, we generated an indicator variable to compare the quality of life 
in patients with values below the 30th centile (<60 mg/L) or higher 
than the 30th centile (≥60 mg/L). The regression models included the 
following variables: ferritin (indicator variable as described), known 
complications to HH (cirrhosis, diabetes, heart disease or osteopenia), 
normal/abnormal pituitary hormones, years since diagnosis, age, gen-
der and Charlson Comorbidity Index (CCI).
Results
 We identified 27 potentially eligible patients. Two declined to par-
ticipate in the study. Twenty-five patients (one with H63D and 24 with 
C282Y mutation) agreed to participate and were included in our anal-
yses (Figure 1).
 The median age was 60 years (range 30 to 79 years) and median 
number of years since the diagnosis was made was 5 (range 1 to 20 
years). Thirteen patients (52%) were men. The ferritin level ranged 
from 16 to 1020 mg/L and the hemoglobin levels from 5.7 to 10.3 
mmol/L. Two patients had hemoglobin below the normal range 5.7 
and 6.9 mmol/l. Both patients were women and had ferritin levels 
above 60 mg/L (100 and 690 mg/L, respectively). The hemoglobin 
levels of patients with ferritin levels above or below the 30th percen-
tile (60 mg/L) were not significantly different (P=0.95). Only a small 
number of patients had co-morbidities. Accordingly, 19 (79%) had a 
Charlson Comorbidity Index (CCI) of zero, four scored 1 point (17%) 
and one scored 5 points (4%). Three patients had congestive heart dis-
ease (12%), one had cirrhosis (4%) and one had osteopenia (4%). Four 
patients had impaired glucose tolerance (16%) and two had diabetes 
(8%). All patients underwent phlebotomy during the previous year. 
The median number of times patients underwent phlebotomy was 13 
(range 3 to 27) for patients diagnosed with HH within five years and 
four (range 0 to 8) for patients diagnosed with HH more than five 
years before inclusion in the study. None were treated with Desferal 
(Table 1).
 Six patients (24%) had a border line peak response to the Synacht-
en test and three (12%) had a low increase. The remaining patients 
had a normal response. Four patients (16%) had impaired glucose 
tolerance and two (8%) had diabetes. Three patients had low IGF-1 
(12%) and two had low prolactin levels (8%). None had clinical evi-
dence of thyroid disease. Among male patients, one (4%) had high LH 
(13 IU/L) but normal testosterone and SHBG. None had hypogonad-
otropic hypogonadism. Among female patients, two post-menopausal 
Figure 1: Frequency plot showing the years since the HH diagnosis.
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women had low LH and FSH levels (8%). Both had normal (low) oes-
tradiol levels, indicating hypogonadotropic hypogonadism. None had 
signs of osteoporosis, but one patient had osteopenia. For further de-
tails, please see supplementary table 1.
Quality of life
The median total SF-36 score was 82.81 (63.97-92.98) (Figure 2).
 There were no differences between the total scores of patients 
with a normal or abnormal Synacthen test (P=0.163), glucose toler-
ance (P=0.859), or IGF-1 (P=0.523) [21,22]. In the univariable linear 
regression analysis, serum ferritin below 60 mg/L was a significant 
predictor of the quality of life (regression coefficient β 0.28; standard 
error [SE] 0.12; P=0.031) (Figure 3).
 None of the remaining covariates were significant in the univari-
able analysis (hemoglobin (P=0.993), borderline response to the syn-
acten test P=0.326; low IGF-1 levels P=0.954; impaired glucose tol-
erance P=0.283; HH related complications P=0.081). After including 
all variables in the model, ferritin level below 60 mg/L was the only 
significant predictor of the quality of life.
Discussion
 This study found that there may be an association between low-
er ferritin levels and a lower health-related quality of life in patients 
with HH undergoing phlebotomy. Based on our limited sample size, 
we cannot make any definite conclusions. It is possible that clinically 
relevant predictors of the quality of life were overlooked. However, 
our results could suggest that the quality of life could be considered 
when making treatment goals. Additional evidence is needed to con-
firm our findings before using our results in clinical practice. Future 
trials could evaluate the potential detrimental effects of phlebotomy 
on quality of life and the trade-off between treatment and the risk of 
complications especially in groups who may theoretically have a lower 
risk of complications (such as the elderly).
 Our study only includes 25 patients and analyses found that ferri-
tin levels below 60 mg/L and HH-related complications were associ-
ated with a lower score on the SF-36 questionnaire. In multivariable 
analyses, only the ferritin level remained statistically significant. Based 
on our sample size, we are unable to make any definite conclusions 
regarding ferritin and the quality of life. In Denmark, phlebotomy is 
adjusted based on ferritin levels. Based on the current availability of 
diagnostic tests and reduced costs associated with genetic testing. Pa-
tients with HH may therefore be diagnosed earlier and therefore un-
dergo treatment for several years. It therefore seems relevant to evalu-
ate the potential effect of ferritin on the quality of life and the potential 
trade-off between treatment and the risk of developing HH-related 
complications.
 We are unable to address causal relationships and explain why fer-
ritin correlates with lower SF-36 scores. We do not have long term 
follow up and were unable to determine the influence of reducing 
All patients Median (range)
Ferritin 79.5 (59.33-101.69) mg/L
Hemoglobin 8.50 (8.20-9.35) mmol/L
S-iron 28.00 (22.26-33.00) umol/L
Transferrin saturation 0.55 (0.46-0.66)
Alanine amino transferase 26.00 (21.26-35.74) U/L
Bilirubin 8.00 (7.00-10.00) umol/L
Albumin 41.5 (39.66-43.34) g/L
International Normalized Ratio 1.00 (0.9-1.1)
Cortisol baseline 258.00 (208.82-355.88) nmol/L
Cortisol 30 minutes 665.50 (532.11-775.83) nmol/L
IGF-1 127.00 (92.59-143.95) ug/L
Prolactin 0.24 (0.19-0.31) nmol/L
TSH 1.59 (1.169-2.00) IU/L
T4 14.45 (12.63-16.04) pmol/L
T3 1.30 (1.10-1.50) pmol/L
Fasting plasma glucose 5.40 (5.10-6.29) mmol/L
Men (n=13)  
LH 3.8 (2.86-6.33) IU/L
Total testosterone 13.10 (10.46-17.17) nmol/L
Free testosterone 43.35 (36.50-57.00) nmol/L
SHBG 41.00 (25.3-1142.31) nmol/L
Women (n=12)  
LH 9.70 (2.57-37.22) IU/L
FSH 5.10 (1.80-7.70) IU/L
Oestradiol 55.00 (40.00-99.00) pmol/L
SHBG 106.00 (55.97-121.69) nmol/L
Table 1: Baseline blood tests of the included patients (n= 25).
Figure 2: Quality of life of included patients assessed using the SF-36 ques-
tionnaire; total score and the sub scores General Health Perception, Bodily 
Pain, Social Functioning, Emotional Wellbeing, Energy/Fatigue, Emotional 
Limitations, Role Limitations Due to Physical Functioning and Physical Func-
tioning.
Figure 3: Quality of life (SF-36 total score) of patients with ferritin <60 ml/L 
or ≥60 mg/L. The figure (box plot) shows the median, interquartile range and 
total range.
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the increased iron levels through phlebotomy. For a young patient, 
achieving ferritin levels between 50 or 100 mg/L reduces the risk of 
HH related complications. In theory, the risk of developing HH re-
lated complications could be less important than the risk of reducing 
the quality of life in elderly patients. The oldest patient included in 
our study was 79 years and 25% were older than 69 years of age. Our 
findings suggest that the quality of life is a factor that may be consid-
ered when setting the therapeutic goal for patients in this age category.
 It is likely that certain subgroups of patients with HH-related com-
plications have an impaired quality of life. We found that the quality 
of life scores were lower in patients with HH related complications, 
but the association was not significant in multivariable analyses af-
ter adjusting for ferritin levels. In addition, we were unable to show 
differences between patients with specific complications. This could 
possibly reflect limited statistical power.
 Previous studies have found that diabetes and hypogonadotrop-
ic hypogonadism are the most common endocrine complications to 
HH. We only identified two patients (8%) with hypogonadotropic 
hypogonadism, which is low compared to other studies [23-26]. Like-
wise, only 16% had impaired glucose tolerance (age ranged 65-79) and 
8% had diabetes. The prevalence of diabetes in the Danish population 
is 5% (all age groups) and 17% have impaired glucose tolerance (age 
group 60-70 years) [27,28]. Thus, the prevalence of diabetes and im-
paired glucose tolerance in our patients with HH is similar to the Dan-
ish population in general [29]. We included several patients who had 
been diagnosed with HH at an early age. Theoretically, our findings 
could reflect a beneficial effect of phlebotomy or that included patients 
had been diagnosed early (at a non-advanced stage). Unlike previous 
studies, we included few patients with cirrhosis or diabetes. The fact 
that a large proportion of patients in previous studies had cirrhosis 
or diabetes suggests that they were diagnosed at an advanced disease 
stage and may therefore have a higher rate of complication to HH [23-
25].
 The prevalence of corticotroph insufficiency in HH is debated. We 
found nine patients without a normal response in the Synacthen test 
[11,30]. We were surprised to find that the Synacthen test result was 
not associated with the quality of life scores. Based on our results, ad-
ditional prospective studies evaluating the quality of life and measur-
ing the Synacthen response after 30 and 60 minutes in patients with 
HH seem relevant. However, at present, regular screening of patients 
does not seem warranted.
Conclusion
 We found that ferritin levels below 60 mg/L are associated with a 
poorer quality of life. Additional studies are needed to evaluate the 
extent to which the quality of life may be included in assessments of 
patients and treatment goals.
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Pt (age) Synacthen OGTT IGF-1 Thyroid Prolactin Oestradiol (women) Testosterone (men) LH FSH
Male patients
1 (61)         
4 (47) Borderline  Low    High  
5 (67)  Impaired  Low T4, T3 + TSH normal     
7 (56)    Low T4,T3 + TSH normal     
10 (69)     Low    
12 (38)         
13 (54) Low increase   Low T3,T4 + TSH normal     
14 (79)         
18 (32) Borderline        
19 (59)         
20 (79)  Diabetes       
21 (65)  Impaired Low      
25 (35) Borderline        
Women
2 (65) Borderline        
3 (63) Low increase   Low T4, T3+TSH normal     
6 (60)   Low  Low  Low Low
8 (49)    Low T3, T4+TSH normal     
9 (31)         
11 (79)  Impaired       
15 (68) Low increase Impaired       
16 (40)         
17 (69)  Diabetes     Low Low
22 (31) Borderline        
23 (31) Borderline     Low Borderline  
24 (72)         
Supplementary Table1: Pituitary function of included patients with Hereditary Hemochromatosis.
